強気
$115.59
シナリオ価格
$93.300
-0.634 (-0.68%)終値時点
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal.
Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.
BofA
$97
2026-08-12
BofA
2026-08-12
目標株価
$97
Canaccord
$94
2026-08-03
Canaccord
2026-08-03
目標株価
$94
BTIG
$105
2026-07-31
BTIG
2026-07-31
目標株価
$105
Raymond James
$100
2026-07-31
Raymond James
2026-07-31
目標株価
$100
Barrington
$114
2026-07-31
Barrington
2026-07-31
目標株価
$114
シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

Investment Opportunities and Risks in Small-Cap Stocks

Merit Medical to Participate in Multiple Investor Conferences

Merit Medical to Participate in Investor Conferences

Merit Medical to Participate in Upcoming Investor Conferences

Merit Medical Systems Reports Strong Q2 2026 Earnings Growth
Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of medical devices used in interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. Its cardiovascular segment consists of four product categories: peripheral intervention, cardiac intervention, custom procedural solutions, and original equipment manufacturer. Its endoscopy segment consists of gastroenterology and pulmonology devices which assist in the palliative treatment of expanding esophageal, tracheobronchial and biliary strictures caused by malignant tumors. Its product portfolio of medical devices and accessories is used in lead management procedures for patients who need a pacemaker, or an implantable cardioverter-defibrillator lead removed or replaced. Its products are used in clinical areas, such as radiology, electrophysiology and more. It also manufactures hemostatic devices under the brand names StatSeal and WoundSeal. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Merit Medical Systems Inc is a good buy right now due to its strong recent performance, including a 9.5% year-over-year revenue growth in Q2 2026, with total revenue reaching $418.8 million. Additionally, the forward P/E ratio of 18.94 suggests potential for growth compared to its current price of $93.30. However, the risk of insider selling has increased by 1341.20% over the last month, which could indicate potential concerns about future performance.
9 analysts cover MMSI: 8 rate it Buy, 1 Hold and 0 Sell. The average price target is 104.63.
投稿はまだありません
登録またはログインして議論に参加本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。